Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02291861 · ClinicalTrials.gov registry record · Phase 3
Addressing Involuntary Movements in Tardive Dyskinesia
A Phase 3 study of Tardive Dyskinesia, sponsored by Auspex Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 298
- Enrollment target
- 20
- Study locations
NCT02291861 is a Phase 3 study of Tardive Dyskinesia that has completed, run by Auspex Pharmaceuticals. The registered enrollment target is 298 participants, above the 89-participant average among 5 other Tardive Dyskinesia trials with a reported enrollment target (235% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT02291861, a Phase 3 study of Tardive Dyskinesia, has completed, sponsored by Auspex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 298 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SD-809
Study Locations (20)
California
- Teva Investigational Site 107 - Anaheim
- Teva Investigational Site 108 - Anaheim
- Teva Investigational Site 123 - Glendale
- Teva Investigational Site 177 - Imperial
- Teva Investigational Site 160 - Irvine
- Teva Investigational Site 106 - Irvine
- Teva Investigational Site 176 - Loma Linda
- Teva Investigational Site 121 - Los Angeles
- Teva Investigational Site 147 - Los Angeles
- Teva Investigational Site 174 - Norwalk
- Teva Investigational Site 170 - Oceanside
- Teva Investigational Site 102 - Orange
- Teva Investigational Site 104 - San Bernardino
- Teva Investigational Site 110 - San Diego
- Teva Investigational Site 169 - San Rafael
Alabama
- Teva Investigational Site 145 - Tuscaloosa
Colorado
- Teva Investigational Site 129 - Englewood
Connecticut
- Teva Investigational Site 139 - New Haven
District of Columbia
- Teva Investigational Site 156 - Washington D.C.
Florida
- Teva Investigational Site 157 - Boca Raton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2014-10-31 |
| Est. Completion | 2016-08-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02291861
The ClinicalTrials.gov registry entry for NCT02291861 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 89-participant average among 5 other Tardive Dyskinesia trials with a reported enrollment target (235% higher). The listed sponsor is Auspex Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tardive Dyskinesia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02291861 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT02291861 about?
NCT02291861 is a clinical study titled "Addressing Involuntary Movements in Tardive Dyskinesia". The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
What is the current status of trial NCT02291861?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 298 participants. The study started on 2014-10-31. Estimated completion is 2016-08-19.
What conditions does trial NCT02291861 study?
This clinical trial studies the following conditions: Tardive Dyskinesia.
What interventions are being tested in trial NCT02291861?
The interventions under investigation include: Placebo (DRUG), SD-809 (DRUG).
Who is sponsoring clinical trial NCT02291861?
This trial is sponsored by Auspex Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02291861 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tardive Dyskinesia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Levetiracetam Treatment of Tardive Dyskinesia
COMPLETED · Phase 3
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes
RECRUITING · NA
-
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.